Screening and diagnosis

Classification and risk stratification

Perioperative care

Quality improvement

Patient education

Nonpharmacologic interventions

Therapeutic procedures

Respiratory support

Follow-up and surveillance

Specific circumstances

Preventative measures

Medical management

Surgical interventions

Inpatient care

Diagnostic procedures

Diagnostic investigations

Insufficient evidence to make a recommendation.

Strongly favor this test or intervention.

The calculator aims to predict the prognosis for individuals with asymptomatic myeloma by assessing the risk of disease progression over five years. This is done using two key laboratory measurements: bone marrow plasmacytosis percentage and serum monoclonal protein levels. 

The user provides the following inputs:
- Bone marrow plasmacytosis percentage, which can be:
  - ">= 10%"
  - "< 10%"

- Serum monoclonal protein level, which can be:
  - ">= 3 g/dL"
  - "< 3 g/dL"

With these inputs, the calculator evaluates the following conditions to assess risk:

- When bone marrow plasmacytosis is "< 10%" and serum monoclonal protein is ">= 3 g/dL", the risk of myeloma progression at five years is 15%.
- When bone marrow plasmacytosis is ">= 10%" and serum monoclonal protein is "< 3 g/dL", there's a 43% risk of progression within five years.
- If both bone marrow plasmacytosis is ">= 10%" and serum monoclonal protein is ">= 3 g/dL", the risk rises to 69% at five years.
- If both parameters are below their respective thresholds (bone marrow plasmacytosis "< 10%" and serum monoclonal protein "< 3 g/dL"), the individual does not meet the criteria for asymptomatic myeloma.

This structured approach clearly identifies and communicates the percentage risk of myeloma progression over a five-year period, helping patients understand their prognosis based on these specific clinical measurements.

The calculator in question is the International Staging System (ISS) for Asymptomatic Myeloma Prognosis. This scoring system is used specifically for patients diagnosed with asymptomatic (smoldering) multiple myeloma, a type of blood cancer. The ISS for Asymptomatic Myeloma Prognosis helps clinicians to stratify patients into different risk groups based on their serum beta-2 microglobulin and albumin levels. This, in turn, aids in predicting the patient's overall survival and progression to symptomatic disease, thereby guiding treatment decisions. The calculator is not applicable to patients with symptomatic multiple myeloma or other types of blood cancers.

Smoldering myeloma

Guidelines

Key sources